Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials
Progression-free survival is an appropriate primary endpoint to support the approval of metastatic melanoma therapies, FDA's Oncologic Drugs Advisory Committee agreed
Progression-free survival is an appropriate primary endpoint to support the approval of metastatic melanoma therapies, FDA's Oncologic Drugs Advisory Committee agreed